

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 487/22, A61K 31/55 // (C07D 487/22, 243:00, 209:00, 209:00, 209:00)	A1	(11) International Publication Number: WO 00/01699
		(43) International Publication Date: 13 January 2000 (13.01.00)

(21) International Application Number: PCT/EP99/04369

(22) International Filing Date: 23 June 1999 (23.06.99)

(30) Priority Data:
09/109,131 2 July 1998 (02.07.98) US(71) Applicant (for all designated States except US): BAYER
AKTIENGESSELLSCHAFT [DE/DE]; D-51368 Leverkusen
(DE).(72) Inventors; and
(75) Inventors/Applicants (for US only): RODER, Hanno [DE/DE];
Sinkesbruch 16, D-40883 Ratingen (DE). LOWINGER,
Timothy, B. [CA/JP]; #203, 5-7 Chitose-cho, Nishinomiya
City, Hyogo 662-0046 (JP). BRITTELLI, David, R.
[US/US]; 240 Stony Creek Road, Branford, CT 06405
(US). VANZANDT, Michael, C. [US/US]; 56 Barker Hill
Drive, Guilford, CT 06437 (US).(74) Common Representative: BAYER AKTIENGE-
SELLSCHAFT; D-51368 Leverkusen (DE).(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG,
BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB,
GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA,
ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ,
UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI
patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR,
NE, SN, TD, TG).**Published***With international search report.*(54) Title: NOVEL INDOLOCARBAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DIS-
EASES AND CANCER

(57) Abstract

Novel indolocarbazole derivatives potentially useful for the treatment of dementias characterized by tau hyperphosphorylation [Alzheimer's disease (AD), frontal lobe degeneration (FLD), argyrophilic grains disease, subacute sclerotic panencephalitis (SSPE) as a late complication of viral infection in the CNS], and cancer.

Internationale Patentanmeldung Nr. PCT/EP03/13322

"N,N-Bridged, Nitrogen-Substituted Carbacyclic Indolocarbazoles As Protein Kinase

Inhibitors"

NAD AG et al.

Ihr Zeichen:

Unser Zeichen: 259-9 PCT

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

NOVEL INDOLOCARBAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCER

Field of the Invention

5 Novel indolocarbazole derivatives potentially useful for the treatment of dementias characterized by tau hyperphosphorylation [Alzheimer's disease (AD), frontal lobe degeneration (FLD), argyrophilic grains disease, subacute sclerotising panencephalitis (SSPE) as a late complication of viral infections in the CNS], and cancer.

Background of the Invention

10 Several dementias, most importantly Alzheimer's disease (AD), are characterized by the formation of intracellular aggregates consisting of the microtubule-associated protein tau, termed neurofibrillary tangles (NFT). The importance of this biochemical abnormality for the clinical syndrome of dementia is illustrated by essentially three facts: (I) there is a close correlation
15 between the state of dementia and the extent and density of NFT in various parts of the cortex [e.g., Bancher C. et al. (1993) *Neurosci. Lett.* 162, 179-182)]; (ii) individual neurons containing NFT in the cell body and/or the neurites are morphologically degenerating, i.e., lose synaptic connections and eventually die [Braak E. et al. (1994) *Acta Neuropathol.* 87, 554-567; Callahan L.M. et al., (1995) *Neurobiol. Aging* 16, 311-314]; (iii) a certain density of NFT in various
20 otherwise unrelated dementias is always associated with dementia, without exception.

The tau protein contained in NFT is severely hyperphosphorylated [Goedert M. et al. (1995) *Neurobiol. Aging* 16, 325-334; Hasegawa M. et al. (1996) *FEBS Lett.* 384, 25-30]. This abnormal phosphorylation renders the protein incompetent to retain its original function, i.e., stabilization of the microtubule cytoskeleton, which is of fundamental importance for the
25 integrity of a neuron [Iqbal K. et al. (1994) *FEBS Lett.* 349, 104-108; Garver T.D. et al. (1996) *J. Neurosci. Res.* 44, 12-20]. This explains the paucity of intact microtubules in AD brains. Phosphorylation alone is responsible for this effect, as dephosphorylation restores the abilities of tau.

30 Because of a relationship between tau phosphorylation, cytoskeletal destabilization, synaptic loss and neuronal degeneration, and ultimately dementia, it would be therapeutically desirable to have pharmaceutical means to interfere with the pathological process of tau hyperphosphorylation.

The characteristics of hyperphosphorylated tau in NFT suggest that the protein kinase

ERK2 is responsible for the pathological tau modification in AD [Drewes G. et al. (1990) *EMBO J.* 11, 2131-2138; Roder H.M. et al. (1993) *Biochem. Biophys. Res. Commun.* 193, 639-647].

ERK2 may exist in an abnormally activated state in AD [Roder H.M. et al. (1995) *J. Neurochem.* 64, 2203-2212]. Inhibition of ERK2 has therefore been suggested as a point of interference to prevent tau hyperphosphorylation, and ultimately to stop NFT formation in neurons.

AD-like tau hyperphosphorylation can be induced in several cellular models (including brain slices), converting tau into a phosphorylation state indistinguishable from tau phosphorylated by ERK2 *in vitro*. The most convincing cellular models involve PP2A inhibition [Sautiér, P.E. et al., *Neurodegeneration* 3, 53-60 (1994); Harris K.A. et al., *Ann. Neurol.* 33, 77-87 (1993)].

However, compounds which inhibit ERK2 and thereby prevent AD-like tau hyperphosphorylation in biological model systems, have previously not been disclosed. Such compounds can be expected to affect processes of neurofibrillary degeneration, tied to tau hyperphosphorylation, in a beneficial manner.

The protein kinases of the ERK family, often termed MAP-kinases, have also been implicated in a variety of important cellular regulation events outside the CNS, such as growth, differentiation and inflammation [e.g., Sale E.M. et al., *EMBO J.* 14, 674-684 (1995); Pages G. et al., *Proc. Natl. Acad. Sci. USA* 90, 8319-8323 (1993); Cowley S. et al., *Cell* 77, 841-852 (1994)]. Consequently, aberrant ERK activation has been implicated in several diseases characterized by loss of growth and differentiation control. In some tumors constitutive ERK activation is associated with cellular transformation due to dominant (activating) mutations in signal transduction proteins or viral proteins interfering with ERK inactivators [Sontag E. et al., *Cell* 75, 887-897 (1993); Leivers S.J. and Marshall C.J., *EMBO J.* 11, 569-574 (1992); Gallego G. et al., *Proc. Natl. Acad. USA* 89, 7355-7359 (1992); Gupta S.K. et al., *J. Biol. Chem.* 267, 7987-7990 (1992)].

The use of the disclosed kinase inhibitors for cancer is also indicated by their ability to inhibit cdc2 kinase. The role of cdc2 and homologous (cdks) kinases in cell cycle control is very well appreciated [Norbury C., and Nurse P., *Annu. Rev. Biochem.* 61, 441-470 (1992)].


Regulation of these enzymes is essential for both commitment to cell cycle from the resting state (START), and ordered transition through several phases of the cell cycle. The need for regulation is reflected in the existence of numerous positive and negative regulatory features of cdks, such as cyclin subunits, inhibiting (Thr) and activating (Tyr) phosphorylations, and

endogenous peptide inhibitors.

Because of this central role of cdks in control of cell cycle and proliferation, they are considered as attractive drug targets for cancer therapies [e.g., Filguera de Azevedo W. et al., *Proc. Natl. Acad. Sci. USA* 93, 2735-2740 (1996)].

Description of Related Art

Indolocarbazole derivatives structurally related to the invention compounds have been described in the literature. The majority of these compounds are derived from the natural product K252a. The production and isolation of K252a was first published by Kase, et al. [*J. of Antibiotics* 39, 1059 (1986)]. Subsequent structure elucidation of K252a, b, c and d were reported in the same year by Yasuzawa et al. [*J. of Antibiotics* 39, 1072 (1986)]. Since the original disclosure and structure elucidation, K252a has been shown to be active in a variety of enzyme and cell-based assays. In particular, these compounds have demonstrated potent protein kinase C (PKC) activity. The most common uses claimed include: cancer, EP 0 323 171 (priority date 24-12-87), EP 0 643 966 (priority date 3-3-93), US 4,923,986 (priority date 9-3-87), US 4,877,776 (priority date 24-12-87), WO 94 27982 (priority date 28-5-93); neurodegenerative disorders, WO 95 07911 (priority date 16-9-93), WO 94 02488 (priority date 24-7-92), antimicrobial [Prudhomme et al., *J. Antibiotics* 47, 792 (1994)], and hypertension [Hachisu et al., *Life Sciences* 44, 1351 (1989)].



K252a

In general, prior art compounds related to the invention are derived from K252a and contain the basic core structure where a tetrahydrofuran moiety is attached to the aglycone forming two glycosidic bonds. Modifications of the K252a core structure include additional substituents on the lactam and indole portions, and modifications of the α -hydroxy ester. The


tetrahydrofuran oxygen in the core structure limits the opportunities for further modification.

Summary of the Invention

Incorporation of a carbon at the tetrahydrofuran oxygen position of the K252a core structure significantly alters the core structure by removing the two glycosidic bonds and replacing the electron rich disubstituted atom with an electronically more neutral tetra-substituted moiety. This change also provides additional opportunities to incorporate functional groups that may enhance properties such as potency, selectivity, stability, toxicity, bioavailability, etc. which can result in an improved biological profile and consequently, a better therapeutic agent.

Compounds containing this important modification are completely inaccessible via synthetic methods used to prepare compounds of the prior art.

According to one aspect of the invention, a composition of matter is provided having the formula of Formula I, as follows:



wherein Z is O or 2H (in which case the double bond is two single bonds),

R1 is H, OH, CO₂R₉, CONHR₉, CH₂OR₉, or CONR₉, R₁₀;

R2 is H or OH; R3 is H or OH; R4 is H or OH;

R5 is H, OH, NR₉R₁₀, NHCOR₉, OCOR₉, OCR₉, halide, COOR₉, or CONR₉R₁₀;

R6 is H, OH, NR₉R₁₀, NHCOR₉, OCOR₉, OCR₉, halide, COOR₉, or CONR₉R₁₀;

R7 is H, OH, O or halide;


R8 is H, OH, halide or nothing (when R7 is O);

R9 is an alkyl of 1-6 carbons, a cycloalkyl of 3-6 carbons or H;

R10 is an alkyl of 1-6 carbons, a cycloalkyl of 3-6 carbons or H.

In certain preferred embodiments, Z is O; R1 is OH, CO₂R₉, CHNHR₉ or CH₂OR₉; R4

is H; R5 is H; R6 is H; and R8 is H. In other preferred embodiments, Z is O; R1 is CO₂CH₃ or CONHCH₃; R2 is H; R3 is OH; R4 is H; R5 is H; and R6 is H. The most preferred compositions of matter are:



According to another aspect of the invention, pharmaceutical compositions are provided. The pharmaceutical compositions include the compositions of matter described above, together with a pharmaceutically acceptable carrier. The preferred pharmaceutical compositions are as described above. Particularly preferred pharmaceutical compositions are those formulated in an oral dosage form.

In some embodiments, the pharmaceutical composition contains the composition of matter in an amount effective for inhibiting abnormal hyperphosphorylation associated with a dementia. In other embodiments, the pharmaceutical composition contains the composition of matter in an amount effective for inhibiting a cdk kinase, such as cdc2 kinase. In still other embodiments, the pharmaceutical composition contains the composition of matter in an amount effective to inhibit cell proliferation, and in certain embodiments to inhibit cancer cell proliferation by cancer cells expressing abnormal amounts of a cdk kinase.

According to another aspect of the invention, a method is provided for inhibiting in a subject a kinase which binds a compound of Formula I. A compound of Formula I is administered to a subject in need of such treatment in an amount effective to inhibit in the subject the kinase activity. Preferred compounds are as described above. In one embodiment, the subject has a dementia and the compound is administered in an amount effective to inhibit abnormal hyperphosphorylation characteristic of the dementia. The dementia can be, among other things, Alzheimer's disease and the compound can be administered in an amount effective to inhibit phosphorylation activity of ERK2 which is characteristic of abnormal tau hyperphosphorylation in Alzheimer's disease.


According to another aspect of the invention, a method is provided for treating a subject

having a cancer which expresses abnormal levels of cdk kinase activity. The method involves administering to a subject in need of such treatment a compound of Formula I in an amount effective to inhibit the cdk kinase activity. In some embodiments, the kinase is cdc2 kinase. The preferred compounds are as described above.

5 According to another aspect of the invention, intermediates for preparing the compounds of Formula I are provided. The intermediates are described in detail in the text below. Particularly important intermediates are those numbered 13, 19 and 24.


According to still another aspect of the invention, a method is provided which involves the use of a compound of Formula I in the preparation of a medicament. In particular
10 embodiments, the medicament is for treating a dementia (e.g. Alzheimer's disease), a proliferative disorder (e.g. a cancer). These and other aspects of the invention are described in greater detail below.

According to another aspect of the invention, intermediates for manufacturing the above compounds are provided. These are compositions of matter comprising:



wherein, $Z=O$ or $2H$ (in which case the double bond is two single bonds);


$R_{11}, R_{12}=H$,



20 R_{11} is not H, then R_{12} is H and when R_{12} is not H, then R_{11} is H;

$R_{13}, R_{13}' = H$ or OP' , and R_{14} is H or OP . Preferably, Z is O and R_{13} and R_{13}' are H . Most preferable the composition of matter is compound 14. P is a protecting group. Preferred Ps for OP are benzyl- and t-butyl-dimethyl silyl. Most preferably the composition of matter is compound 12, 13, 18, 19, 23 or 24.

Other compositions of matter are



Wherein, $Z=O$ or $2H$; R_{13} and $R_{13}' = H$ or OP ; and $R_{14} = O, H, OH$ or OP .

Preferably, Z is O and R_{13} and R_{13}' are H . Most preferably the composition of matter is compound 14.

Mixtures of the foregoing compounds including isomeric mixtures also are contemplated.

Brief Description of the Drawing

Fig. 1 is a drawing of a blot on okadaic acid stimulated cells showing that compound CIII prevent tau hyperphosphorylation caused by okadaic acid.

Fig. 2. Western-blot comparison of tau from human SY5Y cells and from neonatal rat brain in various states of phosphorylation with PHF-tau from AD-brain. Fig. 2A shows human SY5Y cells. Fig. 2B shows neonatal rat brain. Fig. 2C shows PHF-tau from AD-brain.

Fig. 3 is a drawing of a pair of gels showing neonatal rat tau phosphorylation *in vitro* by PK40 without and with prior dephosphorylation by PP2B.

Fig. 4 is a drawing of a blot showing that a compound similar to CIII as an inhibitor of ERK2 prevents abnormal AD-like hyperphosphorylation in a SY5Y cell model system.

Fig. 5. Prevention of AD-like tau hyperphosphorylation in adult rat hippocampal brain slices.

5 In an experimental paradigm similar to SY5Y cells tau hyperphosphorylation is prevented by CII at similar doses as in SY5Y cells. Note that the results with AP422, currently the most specific criterion for AD-like tau hyperphosphorylation, are identical to those with the commonly used mAb AT8, indicating that ERK2 alone is responsible for all okadaic acid induced changes in tau phosphorylation because AT8 but not AP422 reactivity can be induced by kinases other
10 than ERK2.

Detailed Description of the Invention

The present invention relates to certain novel indolocarbazole derivatives that contain a cyclopentanè core structure and may be medicinally useful for the treatment of a variety of
15 disorders, including certain cancers and neurodegenerative disorders. The compounds have ERK2 and/or cdk, and in particular, cdc2, inhibitory activity.

The compounds of the invention, including the preferred compounds have been described above. An aspect of the invention is the replacement of the oxygen molecule of the tetrahydrofuran portion of certain prior art molecules (K252a and analogs) with a carbon atom.
20 Such a class of materials was not available prior to the present invention which also provides a synthetic procedure for preparing this class of materials. The procedure also forms an aspect of the invention. The procedure for making the class of materials is described in detail below in the Examples section.

The most preferred compounds of the invention are indicated and named below:

25

CI. 9,12-Methano-1*H*-diindolo[1,2,3-*fg*:3',2',1'-*kl*]pyrrolo[3,4-*I*][1,6] benzodiazocine-1,3 (2*H*)-dione,9,10,11,12-tetrahydro-8,10,11-trihydroxy-(8 α ,9 α ,10 α ,11 α ,12 α).

30

CII. 9,12-Methano-1*H*-diindolo[1,2,3-*fg*:3',2',1'-*kl*]pyrrolo[3,4-*I*][1,6] benzodiazocine-10-carboxamide, 2,3,9,10,11,12-hexahydro-10-hydroxy-*N*-methyl-1,3-dioxo-

(9 α ,10 β ,12 α).

CIII. 9,12-Methano-1*H*-diindolo[1,2,3-*fg*:3',2',1'-*kl*]pyrrolo[3,4-*l*][1,6]
benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-1,3-
5 dioxomethyl ester, (9 α ,10 β ,12 α).

The invention also involves intermediates for manufacturing the above compounds. The intermediates are described above. Mixtures including isomeric mixtures also may result depending upon the symmetry of the starting molecule. Such mixtures are within the scope of the invention.

10 To prepare the full range of compounds of the invention, only the chemistry described below, together with chemistry well known to those of ordinary skill in the art is required. In particular, modifications of the core structures can be accomplished using routine chemistry such as that used to make similar modifications to k252a, as detailed in WO94/02488, WO94/27982, WO94/04541 and numerous other US patents and published applications showing derivatives of
15 k252a.

A subject as used herein means humans, primates, horses, cows, pigs, sheep, goats, dogs, cats and rodents.

The pharmaceutical preparations of the invention are administered to subjects in effective amounts. An effective amount means that amount necessary to delay the onset of, inhibit the
20 progression of, halt altogether the onset or progression of or diagnose the particular condition being treated. In general, an effective amount for treating a dementia is that amount necessary to affect favorably abnormal hyperphosphorylation characteristic of the dementia. In one embodiment, the effective amount is that amount necessary to affect favorably abnormal tau hyperphosphorylation associated with Alzheimer's disease. In general, an effective amount for
25 treating cancer will be that amount necessary to favorably affect mammalian cancer cell proliferation in-situ. When administered to a subject, effective amounts will depend, of course, on the particular condition being treated; the severity of the condition; individual patient parameters including age, physical condition, size and weight; concurrent treatment; frequency of treatment; and the mode of administration. These factors are well known to those of ordinary
30 skill in the art and can be addressed with no more than routine experimentation. It is preferred generally that a maximum dose be used, that is, the highest safe dose according to sound medical

judgment.

A variety of administration routes are available. The particular mode selected will depend, of course, upon the particular condition being treated, the particular drug selected, the severity of the condition being treated and the dosage required for therapeutic efficacy. The methods of this invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral, rectal, sublingual, topical, nasal, transdermal, intradermal or parenteral routes. The term "parenteral" includes subcutaneous, intravenous, intramuscular, or infusion. Oral routes are preferred.

Dosage may be adjusted appropriately to achieve desired drug levels, locally or systemically. Generally, daily oral doses of active compounds will be from about 0.01 mg/kg per day to 1000 mg/kg per day. It is expected that IV doses in the range of about 1 to 1000 mg/m² per day will be effective. In the event that the response in a subject is insufficient at such doses, even higher doses (or effective higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits.

The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the conjugates of the invention into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the compounds into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

Compositions suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets, or lozenges, each containing a predetermined amount of the active compound. Other compositions include suspensions in aqueous liquors or non-aqueous liquids such as a syrup, an elixir, or an emulsion.

Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the active compounds of the invention, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer based systems such as polylactic and polyglycolic acid, polyanhydrides and

polycaprolactone; nonpolymer systems that are lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-, di and triglycerides; hydrogel release systems; silastic systems; peptide based systems; wax coatings, compressed tablets using conventional binders and excipients, partially fused implants and the like. In addition, a pump-based hardware delivery system can be used, some of which are adapted for implantation.

A long-term sustained release implant also may be used. "Long-term" release, as used herein, means that the implant is constructed and arranged to deliver therapeutic levels of the active ingredient for at least 30 days, and preferably 60 days. Long-term sustained release implants are well known to those of ordinary skill in the art and include some of the release systems described above. Such implants can be particularly useful in treating solid tumors by placing the implant near or directly within the tumor, thereby affecting localized, high-doses of the compounds of the invention.

When administered, the formulations of the invention are applied in pharmaceutically acceptable compositions. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic ingredients. When used in medicine the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof and are not excluded from the scope of the invention. Such salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulfonic, tartaric, citric, methane sulfonic, formic, malonic, succinic, naphthalene-2-sulfonic, and benzene sulfonic. Also, pharmaceutically acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.

Suitable buffering agents include: acetic acid and a salt (1-2% W/V); citric acid and a salt (1-3% W/V); and phosphoric acid and a salt (0.8-2% W/V).

Suitable preservatives include benzalkonium chloride (0.003-0.03% W/V); chlorobutanol (0.3-0.9% W/V); parabens (0.01-0.25% W/V) and thimerosal (0.004-0.02% W/V).

Suitable carriers are pharmaceutically-acceptable carriers. The term pharmaceutically-acceptable carrier means one or more compatible solid or liquid filler, dilutants or encapsulating substances which are suitable for administration to a human or other animal. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which

the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions are capable of being commingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy. Carrier formulations suitable for oral, subcutaneous, intravenous, intramuscular, etc. can be found in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA and in the numerous prior art patents relating to K252a and its analogs.

The compounds useful in the invention may be delivered with other therapeutic agents. In the case of cancer, the compounds would be delivered separately or in the form of anti-cancer cocktails. An anti-cancer cocktail is a mixture of any one of the compounds of this invention with another anti-cancer agent such as an anti-cancer drug, a cytokine, and/or supplementary potentiating agent(s). The use of cocktails in the treatment of cancer is routine. In this embodiment, a common administration vehicle (e.g., pill, tablet, implant, injectable solution, etc.) could contain both the compounds useful in this invention (described above) and the anti-cancer drug and/or supplementary potentiating agent.

Thus, cocktails of non-Formula I compounds and Formula I compounds are contemplated. Non-Formula I anti-neoplastic compounds include:

Antineoplastic: Acivicin; Aclarubicin; Acodazole Hydrochloride; Acronine; Adozelesin; Aldesleukin ; Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide ; Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin ; Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide; Bisantrene Hydrochloride; Bisnafide Dimesylate; Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropirimine ; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin ; Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide ; Cytarabine ; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate; Eflornithine Hydrochloride ; Elsamitrucin; Enloplatin; Enpromate; Epiripidine; Epirubicin Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine; Estramustine Phosphate Sodium; Etanidazole; Ethiodized Oil I 131; Etoposide; Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine ;

Fludarabine Phosphate; Fluorouracil; Flurocitabine; Fosquidone; Fostriecin Sodium;
 Gemcitabine; Gemcitabine Hydrochloride; Gold Au 198 ; Hydroxyurea; Idarubicin
 Hydrochloride; Ifosfamide; Ilmofoesine; Interferon Alfa-2a ; Interferon Alfa-2b ; Interferon Alfa-
 n1; Interferon Alfa-n3; Interferon Beta- I a ; Interferon Gamma- I b; Iproplatin; Irinotecan
 5 Hydrochloride ; Lanreotide Acetate; Letrozole; Leuprolide Acetate ; Liarozole Hydrochloride;
 Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride; Masoprocil; Maytansine;
 Mechlorethamine Hydrochloride; Megestrol Acetate; Melengestrol Acetate; Melphalan;
 Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium; Metoprine; Meturedopa;
 Mitindomide; Mitocarcin; Mitocromin; Mitogillin; Mitomalcin; Mitomycin; Mitosper; Mitotane;
 10 Mitoxantrone Hydrochloride; Mycophenolic Acid; Nocodazole; Nogalamycin; Ormaplatin;
 Oxisuran; Paclitaxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin Sulfate;
 Perfosfamide; Pipobroman; Pipo sulfan; Piroxantrone Hydrochloride; Plicamycin; Plomestane;
 Porfimer Sodium; Porfiromycin ; Prednimustine; Procarbazine Hydrochloride; Puromycin ;
 Puromycin Hydrochloride; Pyrazofurin; Riboprime; Rogletimide; Safingol ; Safingol
 15 Hydrochloride ; Semustine; Simtrazene; Sparfosate Sodium; Sparsomycin; Spirogermanium
 Hydrochloride; Spiromustine; Spiroplatin; Streptonigrin; Streptozocin; Strontium Chloride Sr
 89; Sulofenur; Talisomycin; Taxane; Taxoid; Tecogalan Sodium; Tegafur; Teloxantrone
 Hydrochloride; Temoporfin; Teniposide; Teroxirone; Testolactone; Thiamiprine; Thioguanine;
 Thiotepa; Tiazofurin; Tirapazamine; Topotecan Hydrochloride; Toremifene Citrate; Trestolone
 20 Acetate; Triciribine Phosphate; Trimetrexate; Trimetrexate Glucuronate; Triptorelin; Tubulozole
 Hydrochloride; Uracil Mustard; Uredopa; Vapreotide; Verteporfin; Vinblastine Sulfate;
 Vincristine Sulfate; Vindesine; Vindesine Sulfate; Vinepidine Sulfate; Vinglycinat Sulfate;
 — Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine Sulfate; Vinzolidine Sulfate; Vorozole;
 Zeniplatin; Zinostatin; Zorubicin Hydrochloride. Other anti-neoplastic compounds include:
 25 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene;
 adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox;
 amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide;
 angiogenesis inhibitors: antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic
 protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense
 30 oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators;
 apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine;

axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III
derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstauroporine;
beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor;
bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate;
5 bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin
derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole;
CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS);
castanospermine; cecropin B; cetorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost;
cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B;
10 combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol;
cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentantraquinones; cycloplatan;
cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine;
dehydrodidemnin B; deslorelin; dexifosfamide; dexrazoxane; dexverapamil; diaziquone;
didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin;
15 diphenyl spiromustine; docosanil; dolasetron; doxifluridine; droloxifene; dronabinol;
duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur;
epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists;
etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim;
finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorubicin hydrochloride;
20 forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate;
galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam;
heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene;
idramantone; ilmofofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides;
insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins;
25 iobenguane; iododoxorubicin; ipomeanol, 4-; irinotecan; iroplact; irsogladine; isobengazole;
isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide;
leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor;
leukocyte alpha interferon; leuprolide + estrogen + progesterone; leuprorelin; levamisole;
liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum
30 compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone;
lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine;

mannostatin A; marimastat; masoprocil; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A + myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone + pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullin; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel analogues; paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozele; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; sâfingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive

vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; 5 thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene dichloride; topotecan; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetylrudine; tricyriline; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; 10 urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; zinostatin stimalamer.

Anti-cancer Supplementary Potentiating Agents: Tricyclic anti-depressant drugs (e.g., imipramine, desipramine, amitriptyline, clomipramine, trimipramine, doxepin, nortriptyline, 15 protriptyline, amoxapine and maprotiline); non-tricyclic anti-depressant drugs (e.g., sertraline, trazodone and citalopram); Ca^{++} antagonists (e.g., verapamil, nifedipine, nitrendipine and caroverine); Calmodulin inhibitors (e.g., prenylamine, trifluoroperazine and clomipramine); Amphotericin B; Triparanol analogues (e.g., tamoxifen); antiarrhythmic drugs (e.g., quinidine); antihypertensive drugs (e.g., reserpine); Thiol depleters (e.g., buthionine and sulfoximine) and 20 Multiple Drug Resistance reducing agents such as Cremaphor EL. The compounds of the invention also can be administered with cytokines such as granulocyte colony stimulating factor.

The conjugates of the invention also are useful, in general, for treating mammalian cell proliferative disorders other than cancer, including psoriasis, actinic keratosis, etc.

25 General Preparative Methods

The compounds of the invention may be prepared by use of known chemical reactions and procedures. Nevertheless, the following general preparative methods are presented to aid the reader in synthesizing the inhibitors. More detailed procedures for particular examples are presented below in the experimental section.

30 In the general methods, the following generic descriptions apply. The group designated P represents a protecting group. It may be appreciated by one skilled in the art that a variety of

different protecting groups may be used to protect a potentially reactive functional group (e.g., imide nitrogen, hydroxyl, carboxylic acid) and that the particular choice will depend upon the reaction conditions required to prepare a given target compound. A description of such protecting groups may be found in: *Protective Groups in Organic Synthesis*, Second Edition, T.W. Green and P.G.M. Wuts, John Wiley and Sons, New York, 1991.


5 The group designated X represents a leaving group. It is well-known to those skilled in the art that several different functional groups such as halides, mesylates, tosylates and triflates may serve as leaving groups. It is also known that the choice of a particular leaving group typically depends on such factors as the reactivity of the nucleophile, stability of the compound
10 and ease of synthesis. It is understood that in cases where R represents a potentially reactive functional group such as an alcohol or an amine, appropriate protection and deprotections steps may be required. It is also understood that all variable groups of these methods are as described in the generic description if they are not specifically defined below. When a variable group with a given symbol (i.e., R⁴) is used more than once, each of these groups may be independently
15 varied within the range of the definition of that symbol.

General Method A

The compounds of the invention where the cyclopentane ring is *cis*-dihydroxylated *anti* to the indolocarbazole moiety (R¹, R², Formula I = -OH) are conveniently prepared by method A.
20 The first key step in the process involves the alkylation of the protected indolo[2,3-a]carbazole moiety with a suitable cyclopentane (ene) electrophile. The protected indolo[2,3-a]carbazole moiety is conveniently prepared using methods described in the literature [Lowinger, T.B. et al., *Tetrahedron Lett.* **36**, 8383 (1995), P= paramethoxy benzyl]. Electrophile 11 where R¹⁴ = -H and X = OMs can be prepared from commercially available 3-acetoxy-cyclopentene-2-ol by
25 treatment with methanesulfonyl chloride and triethylamine. Derivatives with R¹⁴ ≠ H can be prepared using standard methods known to those skilled in the art. Treatment of the protected indolo[2,3-a]carbazole with a base like Cs₂CO₃ or NaH in a polar aprotic solvent like DMF followed by addition of the alkylating agent (11) provides the desired monoalkylated material. Conversion of 12 to alcohol 13 can be accomplished by a variety of methods well-known to
30 those skilled in the art. One method involves a transesterification reaction where the acetate moiety is transferred to an alcoholic solvent by treatment with catalytic NaCN. Cyclization of

alcohol 13 to form the 7-membered ring of 14 can be carried out using triphenylphosphine and diethyl azodicarboxylate in a reaction known as the Mitsunobu reaction. An excellent review of this chemistry is described in *Organic Reactions* 42, 335 (1992). Subsequent oxidation of 14 to diol 15 can be accomplished by an OsO₄ catalyzed *cis*-hydroxylation. The oxidation reaction is conveniently carried out using a catalytic amount of OsO₄ with a reoxidant such as *N*-methylmorpholine *N*-oxide (NMO) in an aqueous tetrahydrofuran (THF) or acetone solution. Similar oxidation using other metal-like Manganese and Ruthenium can also be used. The method used to remove the protecting group P from intermediate 15 will depend on the particular group used. Deprotection of 15 where P is p-methoxybenzyl can be accomplished by treatment with trifluoroacetic acid (TFA) at elevated temperatures. Addition of a cation scavenger like anisole to the reaction mixture often results in higher yields. Those skilled in the art will appreciate that different protecting groups may be required depending on the reactivity of the various R groups.

Scheme 1 Method A




General Method B

The compounds of the invention where the cyclopentane ring is *cis*-dihydroxylated *anti* to the indolocarbazole moiety (R¹, R², Formula I = -OH) and R¹⁴ = hydroxyl or a substituent derived from the hydroxyl group are conveniently prepared by method B. The first key step in the process involves the alkylation of the protected indolo[2,3-a]carbazole moiety with a suitable

electrophile (17). The protected indolo[2,3-a]carbazole can be prepared using methods described in the literature [Lowinger T.B. et al., *Tetrahedron Lett.* **36**, 8383 (1995), P = paramethoxy benzyl]. Alkylation of the protected indolo[2,3-a]carbazole moiety with mesylate 17 (Johnson et al. ...) using a base like NaH or Cs₂CO₃ in a polar aprotic solvent like DMF provides the mono-alkylated product 18. Deprotection of the acetonide moiety using standard hydrolysis conditions provide dialcohol 19. Dialcohol 19 can be converted to the cyclized product 20 by hydroxyl directed epoxidation and subsequent intramolecular alkylation, or cyclization using Mitsunobu conditions followed by *cis*-hydroxylation using O₃/O₄. Deprotection of 20 where P is p-methoxybenzyl can be accomplished by treatment with trifluoroacetic acid (TFA) at elevated temperatures. Addition of a cation scavenger like anisole to the reaction mixture often results in higher yields. Those skilled in the art will appreciate that different protecting groups may be required depending on the reactivity of the various R groups.

Scheme 2 General Method B




General Method C

The compounds of the invention with an α -hydroxy carboxyl moiety as illustrated in Scheme 3 are conveniently prepared using method C. The first key step in the process involves alkylation of the protected indolo[2,3-a]carbazole moiety with a suitable cyclopentene electrophile. Protected indolo[2,3-a]carbazole moiety 10 is conveniently prepared using methods

described in the literature [Lowinger T.B. et al., *Tetrahedron Lett.* 36, 8383 (1995) P =
paramethoxy benzyl]. Electrophile 22 can be prepared from cyclopentene-3-ol by treatment with
methanesulfonyl chloride and triethylamine. Cyclopentene-3-ol can be prepared according to
the procedures described in *J. Org. Chem.* 32, 4138 (1967). Treatment of the protected
5 indolo[2,3-a]carbazole with a base like Cs_2CO_3 or NaH in a polar protic solvent like DMF
followed by addition of the alkylating agent (22) provides the desired mono-alkylated material
23. Subsequent activation of the double bond can be accomplished by an OsO_4 with a reoxidant
such as *N*-methyl morpholine *N*-oxide (NMO) in an aqueous THF or Acetone solution.
Cyclization of diol 24 using Mitsunobu conditions provides the bis alkylated adduct 25. A recent
10 review of this Mitsunobu chemistry can be found in *Organic Reactions*, 42, 335 (1992).
Oxidation of alcohol 25 to ketone 26 can be accomplished using a wide variety of reagents and
reaction conditions well-known to those skilled in the art. One common method involves the use
of chromium based reagents like pyridinium chlorochromate (PCC) in an aprotic solvent such as
methylenechloride. A wide variety of nucleophiles may be added to the ketone moiety in a
15 stereoselective manner. To generate an α -hydroxy carboxyl group it is convenient to add
carboxylic acid anion equivalent. A general review of this methodology is described in
"Unpoled Synthons", Hase T.A., Ed.; John Wiley & Sons, 1987. One example of a carboxylic
acid anion equivalent is an ortho thioformyl carbanion [e.g., $\text{LiC}(\text{SMe})_2$]. This nucleophile is
conveniently prepared by treating tris(methylthio)methane with a strong base like *n*-BuLi. In
20 general, the addition of the nucleophile to the ketone occurs opposite to the aglycone moiety.
The thiocarboxylic acid orthoester is easily hydrolyzed by a Lewis acid like boron trifluoride
etherate or mercury (II) oxide. Either an ester or a carboxylic acid can be obtained from the
orthoester depending on the reagents used in the hydrolysis. The methyl ester (28, Q = OMe) is
conveniently obtained by treating the orthoester with mercury (II) chloride and mercury (II)
25 oxide in aqueous methanol. The corresponding carboxylic acid (28, Q = OH) can be obtained by
treatment with boron trifluoride etherate in an aqueous THF solution. Once formed, the
carboxylic acid can be used as an intermediate to prepare amides (28, Q = NHMe) via a coupling
reagent like carbonyldiimidazole (CDI). These procedures are well-known to those skilled in the
art. The method used to remove the protecting group P from intermediate 28 will depend on the
30 particular group used. Deprotection of 28 where P is *p*-methoxybenzyl (PMB) can be
accomplished by treatment with trifluoroacetic acid (TFA) at elevated temperatures. Addition of

a cation scavenger like anisole to the reaction mixture often results in a higher yielding reaction. Those skilled in the art will appreciate that different protecting groups may be required depending on the reactivity of the various R groups.

5 Scheme 3 Method C




EXAMPLES

Example 1: Synthesis of 9,12-Methano-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-l][1,6]benzodiazocine-1,3 (2H)-dione, 9,10,11,12-tetrahydro-10,11-dihydroxy-(9 α ,10 α ,11 α ,12 α)


In order to develop more compounds having ERK2 inhibiting activity a series of synthetically modified derivatives of K252a were prepared. The preparation of four such compounds in which the preferential inhibition of PK40 over PKC/PKA was maintained by a margin of at least 2-3 orders of magnitude is described in Examples 1-4.

It is believed that these ATP analogs act as inhibitors of PK40(ERK2) by binding to the ATP binding site on PK40. PK40 seems to be particularly susceptible to inhibition by ATP analogs, resulting in similar selectivity to K252a and ATP itself.




Step 1. A solution of (1S,4R)-cis-4-acetoxy-2-cyclopentene-1-ol (53 mg, 0.37 mmol) and triethylamine (0.77 mL, 0.55 mmol) in a mixture of benzene (0.8 mL) and pentane (0.8 mL) was cooled to -5°C - 0°C and treated with methanesulfonyl chloride (0.043 mL, 0.56 mmol) at a rate such that the temperature remained below 0°C . A white precipitate was observed.

In a separate round bottom flask, a solution of aglycone [prepared using the protocols described in *Tetrahedron Letters* 36, 8383 (1995)] (319 mg, 0.72 mmol) in DMF (6.0 mL) was cooled to -5°C - 0°C for one hour, the reaction mixture was quenched with brine and extracted with ethyl acetate. The organic phase was dried over Na_2SO_4 , filtered and concentrated *in vacuo*. Purification by MPLC (silica, 50-100% CH_2Cl_2 -hexanes) gave the target compound (55 mg, 22 26%) as a yellow solid. ^1H NMR ($\text{DMSO}-d_6$) δ 12.19 (s, 1 H), 9.19 (d, $J = 2.7$ Hz, 1 H), 9.10 (d, $J = 2.7$ Hz, 1 H), 7.78 - 6.87 (m, 10 H), 6.81 (m, 1 H), 6.51 (m, 1 H), 6.36 (m, 1 H), 6.13 (m, 1 H), 4.82 (s, 2 H), 3.69 (s, 3 H), 2.68 (m, 2H), 2.10 (s, 3 H); MS (FAB-LSIMS) m/z (relative intensity) 569 (M^+ , 44), 508 (32), 462 (100), 444 (50), 429 (30); TLC: R_f 0.4 (silica, 7% EtOAc-hexanes); MP $>200^{\circ}\text{C}$.



Step 2. A solution of the acetate from step 1 (30 mg, 0.05 mmol) and sodium cyanide (10 mg, 0.2 mmol) in ethanol (2.0 mL) was heated at reflux until no starting material was observed by TLC (2 h). The mixture was concentrated *in vacuo*, washed in water (20 mL) and extracted with EtOAc (20 mL). The organic extract was dried over Na_2SO_4 and concentrated to give a yellow oil. Purification by MPLC (silica, 0-15% EtOAc- CH_2Cl_2) afforded the target alcohol (27 mg, 90%) as an orange powder. ^1H NMR ($\text{DMSO}-d_6$) δ 12.17 (s, 1 H), 9.19 (d, $J = 2.6$ Hz, 1 H), 9.10


(d, $J = 2.5$ Hz, 1 H), 7.78 - 6.87 (m, 10 H), 6.79 (m, 1 H), 6.28 (m, 2 H), 5.25 (m, 2 H), 4.83 (s, 2 H), 3.68 (s, 3 H), 2.54 (m, 2H); TLC (silica, 10% EtOAc-CH₂Cl₂).



10

Step 3. The alcohol from step 2 was added to a solution of diethyl azodicarboxylate (65.1 mg, 0.46 mmol) and triphenylphosphine (141 mg, 0.54 mmol) in tetrahydrofuran (4.0 mL). After stirring overnight at room temperature, the reaction was quenched with brine and extracted with EtOAc. The organic phase was dried over Na₂SO₄, filtered and concentrated *in vacuo*. The resulting brown oil was purified by MPLC (silica, 20-30% EtOAc-hexanes) to give the cyclized product (60mg, 31%) as a yellow powder. ¹H NMR (DMSO-d₆) δ 9.07 (s, 1 H), 9.04 (s, 1 H), 8.02 - 6.87 (m, 10 H), 6.41 (s 2 H), 6.22 (m, 2 H), 4.83 (s 2 H), 3.68 (s, 3 H), 3.15 (m, 1 H), 2.71 (m, 1 H); TLC: R_f 0.75 (silica, 50% EtOAc-hexanes).

20




25

Step 4. A solution of the imide from step 3 (49.1 mg, 0.096 mmol) in anisole (0.68 mL) was stirred at room temperature for fifteen minutes and cooled to over 0°C. Over the next twenty minutes, trifluoroacetic acid (6.8 mL) was added to the solution. After allowing the orange mixture to warm to room temperature, the solution was heated to reflux overnight. After


30

removing the solvent *in vacuo*, the resulting brown oil was washed with saturated. aq. NaHCO₃ (20 mL) and extracted with EtOAc (25 mL). The organic phase was dried over Na₂SO₄, filtered and concentrated *in vacuo*. Purification of the resulting oil *via* flash chromatography (silica, 0-10% EtOAc-CH₂Cl₂) gave the deprotected imide as an orange powder (34.9 mg, 93%). ¹H NMR (DMSO-d₆) δ 11.06 (s, 1 H), 9.06 (s, 1 H), 6.22 (d, *J* = 2.2 Hz, 2 H), 3.12 (m, 1 H), 2.70 (m, 1 H); MS (FAB-LSIMS) *m/z* (relative intensity) 390 (M+H, 60), 369 (32), 347 (62), 319 (30), 305 (18), 293 (22), 277 (100), 267 (18), 254 (28), 241 (14), 207 (14); TLC: R_f 0.50 (5% EtOAc-CH₂Cl₂). MP>230°C.




Step 5 - Preparation of Example 2. A solution of the imide from step 4 (14.4 mg, 0.04 mmol) and *N*-methylmorpholine (0.2 mL) in tetrahydrofuran (0.4 mL) was treated with osmium tetroxide (0.1 mL, 1.0 M in THF) and stirred at room temperature for one hour (until no starting material remained by TLC, EtOAc). The reaction mixture was quenched with NaHSO₃ (1.5 mL, 2 M aqueous solution) and stirred vigorously for 1 hour. The solution was diluted with brine and extracted with EtOAc. The organic phase was dried over Na₂SO₄ and concentrated *in vacuo*. The resulting yellow oil was purified by HPLC (0-3% MeOH-chloroform) to afford the target diol as a red-orange powder (9.5 mg, 61%). ¹H NMR (DMSO-d₆) δ 11.05 (s, 1 H), 9.05 (s, 1 H), 9.02 (s, 1 H), 7.85 (s, 1 H), 7.65 (m, 2 H), 7.39 (m, 2 H), 5.51 (m, 2 H), 5.39 (m, 2 H), 4.06 (s, 2 H), 3.27 (m, 1 H); 2.40 (m 1 H). MS (FAB-LSIMS) *m/z* (relative intensity) 424 (M+H, 34), 381 (24), 362 (12), 310 (16), 185 (42), 121 (72), 93 (100), 55 (50); TLC: R_f 0.2 (EtOAc-); MP>230°C.


Example 2: Synthesis of 9,12-Methano-1*H*-diindolo[1,2,3-*fg*:3',2',1'-*kl*]pyrrolo[3,4-*l*][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-1,3-dioxomethyl ester, (9α,10β,12α).



Step 1. A solution of cyclopentene-3-ol [prepared using the protocols described in *J. Org. Chem.* 32, 1967, 4138] (2.1 g, 25.0 mmol) and triethylamine (3.60 mL, 25.8 mmol) in CH_2Cl_2 (15.0 mL) was cooled to 0°C and treated with methanesulfonyl chloride (1.9 mL, 24.5 mmol) at a rate such that the temperature remained below 0°C . After warming to room temperature and stirring for two hours, the reaction mixture was quenched with brine (40 mL) and extracted with CH_2Cl_2 (90 mL). The organic extract was dried over Na_2SO_4 , filtered and concentrated *in vacuo*. Purification by MPLC (silica, 15-40% EtOAc-hexanes) gave the desired mesylate as a pale yellow liquid (3.74g, 92%). ^1H NMR (CDCl_3) δ 5.74 (m, 2 H), 5.38 (m, 1 H), 3.02 (s, 3 H, 2.84 - 2.63 (m, 4 H); TLC: R_f 0.4 (40% EtOAc-hexanes).




Step 2. A solution of the protected aglycone [prepared using the protocols described in *Tetrahedron Lett.* 36, 1995, 8383] (3.72 g, 8.3 mmol) in dimethylformamide (50 mL) was heated to $60 - 65^\circ\text{C}$ and treated with cesium carbonate (10.9 g, 33.3 mmol). The resulting dark red mixture was stirred for 30 min. Over the next four hours, the mesylate from step 1 (4.04 g, 24.9 mmol) was added in 500 mg portions and mixture stirred for two days at $65 - 70^\circ\text{C}$. After cooling to room temperature, the reaction mixture was quenched with brine (300 mL) and extracted with EtOAc (300 mL). The organic phase was dried over Na_2SO_4 , filtered and concentrated *in vacuo*. Purification by flash chromatography (silica, 25-25% CH_2Cl_2 -hexanes) gave the desired mono alkylated product as an orange powder (2.0g, 47%). ^1H NMR ($\text{DMSO}-d_6$) δ 12.13 (s, 1 H), 9.21 (d, $J = 2.6$ Hz, 1 H), 9.09 (d, $J = 2.7$ Hz), 7.77 - 6.87 (m, 10 H), 6.07 (s, 2 H), 4.79 (s, 2 H), 3.68 (s, 3 H), 3.25 - 3.17 (m, 2 H), 3.01 - 2.93 (m, 2 H); MS (FAB-LSIMS) m/z (relative intensity) 511 (M^+ , 20), 419 (14), 391 (30), 378 (64) 363 (54), 255 (8); TLC: R_f 0.5 (60% EtOAc-hexanes).



5

Step 3. A solution of the cyclopentene intermediate from step 2 (1.67 g, 3.26 mmol), and 4-methylmorpholine-*N*-oxide (60% aqueous solution, 0.55 mL, 5.31 mmol) in tetrahydrofuran (39 mL) was treated with OsO₄ (3.91 mL, 0.1 M in THF, 0.12 eq) and stirred overnight. After
10 quenching mixture with aqueous 2.0 M sodium bisulfite solution and stirring for thirty minutes, the solution was extracted with EtOAc (150 mL) and washed with brine (300 mL). The organic phase was dried over Na₂SO₄, filtered and concentrated *in vacuo*. Purified by flash chromatography (silica 0 - 10% MeOH-EtOAc) gave the target compound as a orange-yellow solid (1.43 g, 80%). ¹H NMR (DMSO-*d*₆) δ 12.04 (s, 1 H), 9.23 (d, *J* = 2.7 Hz, 1 H), 9.10 (d, *J* =
15 2.7 Hz, 1H), 7.80 - 6.87 (m, 10 H), 6.11 (m, 1 H), 4.81 (m, 4 H), 4.74 (m, 2 H), 3.68 (s, 3 H); MS (FAB-LISMS) *m/z* (relative intensity) 545 (M⁺, 18), 438 (40), 338 (10), 255 (8); TLC: R_f 0.2 (5% MeOH-chloroform).

20




25


Step 4. A solution of the diol intermediate from step 3 (277 mg, 0.42 mmol) and triphenylphosphine (383 mg, 1.46 mmol) in tetrahydrofuran (26 mL) was treated with diethyl azodicarboxylate (0.16 mL, 0.98 mmol) at a rate such that the resulting orange-red color of the reaction mixture was allowed to return to its initial yellow color. After the addition was
30 completed, the mixture was stirred for two days and subsequently heated to reflux for one day. The reaction mixture was quenched with brine (100 mL) and extracted with EtOAc (160 mL).

- 27 -

The organic phase was dried over Na_2SO_4 , filtered and concentrated *in vacuo*. Purification of the resulting oil by MPLC (silica, 0-20% EtOAc- CH_2Cl_2) afforded the cyclized product as an orange powder (165 mg, 75%). ^1H NMR ($\text{DMSO}-d_6$) δ 9.13 (d, $J = 2.7$ Hz, 1 H), 9.08 (d, $J = 2.7$ Hz, 1 H), 8.04 - 6.96 (m, 10 H), 5.98 (m, 1 H), 5.70 (m, 1 H), 5.41 (m, 1 H), 4.89 (s, 2 H), 4.29 (m, 1 H), 3.77 (s, 3 H), 3.22 (m, 1 H), 2.68 (m, 1 H), 2.45 (m, 1 H), 2.05 (m, 1 H); MS (FAB-LSIMS) m/z (relative intensity) 527 (M^+ , 32), 420 (62); TLC: R_f 0.5 (30% EtOAc- CH_2Cl_2).




Step 5. A solution of pyridinium chlorochromate (89 mg, 0.41 mmol) in CH_2Cl_2 (2.0 mL) was treated with the alcohol from step 4 (140 mg, 0.27 mmol) as a solution in CH_2Cl_2 (18 mL). A second portion of pyridinium chlorochromate (40 mg) was added to the brown mixture. After stirring the mixture for 2 hours, the solution was filtered through a short pad of silica gel and concentrated *in vacuo*. Purification by flash chromatography (silica, 80-100% CH_2Cl_2 -hexanes) afforded the target ketone as a yellow powder (108 mg, 77%). ^1H NMR ($\text{DMSO}-d_6$) δ 9.05 (d, $J = 2.6$ Hz, 1 H), 9.03 (d, $J = 2.4$ Hz, 1 H), 7.98 - 6.86 (m, 10 H), 6.14 (m, 1 H), 5.58 (m, 1 H), 4.82 (s, 2 H), 3.68 (s, 3 H), 3.44 (m, 1 H), 3.22 (m, 1 H), 3.00 (m, 1 H), 2.50 (m, 1 H); MS (FAB-LSIMS) m/z (relative intensity) 525 (M^+ , 14), 418 (30), 281 (34), 185 (100), 147 (38), 121 (66); TLC: R_f 0.6 (20% EtOAc- CH_2Cl_2).




SUBSTITUTE SHEET (RULE 26)

Step 6. A solution of *tris*(methylthio)methane (0.16 mL, 1.15 mmol) in tetrahydrofuran (3.0 mL) was cooled to -78°C and treated with *n*-butyl lithium (0.59 mL, 1.6 M, 0.94 mmol). After stirring for twenty minutes, a solution of the ketone from step 5 (199 mg, 0.38 mmol) in tetrahydrofuran (6.0 mL) was added to the reaction mixture and stirred for two hours. After quenching with a saturated ammonium chloride solution (10 mL) and warming to room temperature, the reaction mixture was diluted with water (10 mL) and extracted with EtOAc (90 mL). The organic layer was separated, dried over Na_2SO_4 and concentrated *in vacuo*. Purification of the resulting oil by flash chromatography (silica, 20% EtOAc-hexanes) provided the addition product as a yellow solid (67 mg, 26%). ^1H NMR ($\text{DMSO}-d_6$) δ 9.06 (m, 2 H), 8.17 - 6.87 (m, 10 H), 5.74 (m, 1 H), 5.05 (s, 1 H), 4.85 (s, 2 H), 3.69 (s, 3 H), 3.01 (m, 2 H), 2.17 (s, 9 H); MS (FAB-LSIMS) m/z (relative intensity) 679 (M^+ , 12), 572 (22), 488 (24), 310 (100), 284 (86); TLC: R_f 0.8 (50% EtOAc-hexanes).




Step 7. A solution of the thiocarboxylic acid orthoester intermediate from step 6 (50 mg, 0.074 mmol) in tetrahydrofuran (5.0 mL) was treated with methanol (12.0 mL), water (1.0 mL), mercury (II) oxide (84 mg, 0.39 mmol) and mercury (II) chloride (236 mg, 0.87 mmol). The reaction mixture was heated to reflux. The solution was diluted with brine (30 mL) and extracted with CH_2Cl_2 (60 mL). The organic phase was dried over Na_2SO_4 , filtered and concentrated *in vacuo*. Purification by flash chromatography (silica, 0-3% EtOAc- CH_2Cl_2) gave the target ester as an orange solid (18 mg, 42%). ^1H NMR (CDCl_3) δ 9.25 (m, 2 H), 7.60 - 7.40 (m, 8 H), 6.88 - 6.85 (m, 2 H), 5.61 (m, 1 H), 5.40 (m, 1 H), 4.93 (s, 2 H), 4.03 (s, 3 H), 3.77 (s, 3 H), 3.21 (m, 2

H), 2.88 (m, 1 H), 2.77 (m, 1 H), 1.95 (m, 1 H); MS (FAB-LSIMS) m/z (relative intensity) 585 (M^+ , 8), 478 (8), 277 (11), 185 (100); TLC: R_f 0.15 (50% EtOAc-hexanes).




Step 8. Preparation of Example 3. A solution of the ester intermediate from step 7 (18 mg, 0.03 mmol) was dissolved in anisole (0.3 mL) over fifteen minutes and subsequently treated with trifluoroacetic acid (2.7 mL). The reaction mixture was heated to reflux for 2 hours (until no starting material remained by TLC, 5% EtOAc- CH_2Cl_2). The solution was concentrated *in vacuo*. Purification by flash chromatography (silica, 10-20% EtOAc- CH_2Cl_2) afforded the target imide as a yellow solid (11.0 mg, 77%). 1H NMR (DMSO- d_6) δ 11.04 (s, 1 H), 9.03 (m, 2 H), 7.90 - 7.33 (m, 6 H), 5.81 (m, 1 H), 5.71 (m, 1 H), 5.54 (s, 1 H), 3.83 (s, 3 H), 3.08 (m, 2 H), 2.76 (m, 1 H), 1.71 (m, 1 H); ^{13}C NMR (DMSO- d_6) δ 175.3 (C=O), 171 (C=O imide), 170, (C=O imide,), 142.0, 140.0, 129.7, 128.4, 126.8, 126.7, 124.4, 121.3, 121.3, 121.2, 120.4, 120.2, 119.6, 119.5, 119.4, 115.3, 110.4, 109.7, 81.1 (COH), 61.7 (CHN), 55.2 (CHN), 52.07 (OCH3), 45.3, (CH2), 39.0 (CH2); MS (FAB-LSIMS) m/z (relative intensity) 466 ($M+H$, 14), 423 (6), 185 (28), 93 (100); TLC: R_f 0.2 (5% EtOAc- CH_2Cl_2); MP > 230°C.

Example 3: Synthesis of 9,12-Methano-1*H*-diindolo[1,2,3-*fg*:3',2',1'-*kl*]pyrrolo[3,4-*I*][1,6]benzodiazocine-1,3,10 (2*H*,9*H*)-trone, 11,12-dihydro.




Step 1. Preparation of Example 4. A solution of the ketone for step 5 of example 2 (15 mg, 0.029 mmol) was dissolved in anisole (0.3 mL) over fifteen minutes and subsequently treated with trifluoroacetic acid (2.7 mL). The mixture was heated to reflux temperatures until no starting material was detected by TLC (10% EtOAc-CH₂Cl₂). The solution was concentrated under reduced pressure and purified by flash chromatography (silica, 0-10% EtOAc-CH₂Cl₂) to afford the target ketone (8.9 mg, 77%) as a yellow solid. ¹H NMR (CDCl₃) δ 9.16 (m, 2 H), 7.68 - 7.24 (m, 7 H), 5.90 (m, 1 H), 5.23 (m, 1 H), 3.32 (m, 1 H), 3.14 - 2.93 (m, 2 H), 2.52 (m, 1 H); MS (FAB-LSIMS) *m/z* (relative intensity) 405 (M+H, 12), 354 (12), 324 (18), 224 (18), 191 (52); TLC: R_f 0.4 (10% EtOAc-CH₂Cl₂); MP>225°C.

Example 4: Synthesis of 9,12-Methano-1*H*-diindolo[1,2,3-*fg*:3',2',1'-*kl*]pyrrolo[3,4-*l*][1,6]benzodiazocine-10-carboxamide, 2,3,9,10,11,12-hexahydro-10-hydroxy-*N*-methyl-1,3-dioxo-(9α,10β,12α).



Step 1. A solution of the thiocarboxylic acid ortho ester intermediate from step 6 of example 2 (28 mg, 0.04 mmol) in 20% H₂O-tetrahydrofuran (1.3 mL) was treated with mercury (II) oxide (45 mg, 0.21 mmol) and boron trifluoride diethyl etherate (0.073 mL, 0.59 mmol). The reaction mixture was stirred for two hours at room temperature [until only one major spot was seen by TLC (2:3:95 acetic acid-methanol-CH₂Cl₂)], diluted with water (10 mL) and extracted with EtOAc (20 mL). The organic phase was dried over Na₂SO₄, filtered and concentrated *in vacuo*. Purification by flash chromatography (silica, 0-10% methanol-CH₂Cl₂) afforded the target acid as an orange solid (76%, 18.0 mg). MS(FAB-LSIMS) *m/z* (relative intensity) 571(M+, 8), 464 (14), 381 (32), 330 (88), 181 (100); TLC: R_f 0.3 (2:3:95 acetic acid-methanol-CH₂Cl₂).


- 31 -



5

Step 2. A solution of carboxylic acid from step 1 (20 mg, 0.034 mmol) in tetrahydrofuran (2.5 mL) was cooled to 0°C and treated with 1,1'-carbonyldiimidazole (60 mg, 0.37 mmol) and stirred for ten minutes. A solution of approximately 50% methylamine-tetrahydrofuran (2 mL) was quickly added to the reaction. After five minutes, no starting material was observed by TLC (20% EtOAc-CH₂Cl₂) and the reaction mixture was quenched with a saturated citric acid solution (3.0 mL). After warming to room temperature, the solution was diluted with brine (15 mL) and extracted with EtOAc (20 mL). The organic phase was dried over Na₂SO₄, filtered and concentrated *in vacuo*. Purification by flash chromatography (silica, 0-20% EtOAc-CH₂Cl₂) gave the target methyl amide (7.0 mg, 35%). MS (FAB-LSIMS) *m/z* (relative intensity) 584 (M⁺, 6), 477 (8), 253 (8), 169 (84), 132 (30), 85 (100); TLC:R_f 0.3 (20% EtOAc-CH₂Cl₂).

15



20

Step 3. Preparation of example 5. A solution of the protected methyl amide from step 2 (7.0 mg, 0.01 mmol) was dissolved in anisole (0.5 mL) over ten minutes and subsequently treated with trifluoroacetic acid (4.5 mL). The mixture was heated to reflux for eight hours [no starting material was observed by TLC (50% EtOAc-CH₂Cl₂)]. The mixture was concentrated *in vacuo* and purified by flash chromatography (silica, 10-20% EtOAc-CH₂Cl₂) to afford the methyl amide as a orange powder (3.4 mg, 61%). ¹H NMR (DMSO-d₆) δ 11.03 (s, 1H), 9.04 (m, 2H), 7.94-7.32 (m, 7H), 5.81 (m, 1H), 5.59 (s, 1H), 5.41 (1H), 3.25-3.05 (m, 2H), 2.66 (d, *J* = 1.5 Hz, 3H), 2.64 (m, 1H), 1.74 (m, 1H); MS (FAB-LSIMS) *m/z* (relative intensity) 465 (M⁺H, 14), 361 (82),

30

346 (38), 322 (100), 315 (38); TLC: R_f 0.4 (50% EtOAc-CH₂Cl₂); MP > 230°C.

Example 5: Preparation and Analysis of Kinases for Inhibitor Assays.

Preparation of Kinases:

5 Preparation of PKC: PKC was purified from rat brain using the method of Woodgett J.R. and Hunter T., *J. Biol. Chem* 262, 4836-4843 (1987).

Preparation of cAMP-dependent Kinase: The catalytic subunit of bovine heart PKA was obtained commercially from Sigma.

10 Preparation of cdc2 Kinase: Human cdc2 kinase was prepared from nocodazole-arrested HeLa cells according to Marshak D.M. et al., *J. Cell Biochem.*, 45, 391-400 (1991).

Preparation of ERK2: Recombinant human ERK2 with a N-terminal histidine (his) tag was prepared as follows: An ERK2 cDNA clone was amplified from a human frontal cortex library by PCR with primers matching the published human sequence [Gonzales F.A. et al, *FEBS Lett.* 304, 170-178 (1992)]. The histidine tag was introduced by site-directed mutagenesis. The cDNA was cloned into a pET-14b (Novagen) vector and transfected into the E. coli lysogen strain BI21pLysS. Single colony transformants were grown in LB medium containing 35 mg/ml chloramphenicol to maintain pLysS and 50 mg/ml kanamycin to an O.D.₆₀₀ OF 0.6. The culture was then induced with 0.4 mM IPTG for 4 hours. The expressed ERK2 protein was then analyzed on a 10% SDS PAGE by both coomassie blue staining and anti-ERK Western blotting. 20 Bacterial pellets from 0.5 - 1 [cultures were freeze-thawed at -78°C and homogenized by ultrasonication for 3 min in 15 ml Ni²⁺- column buffer (20 mM Tris HCL pH 7.9, 0.5 M NaCl, 5 mM imidazole, Novagen). After centrifugation at 35,000 x g for 30 min supernatants were loaded onto a 1 ml Ni²⁺ charged resin (Novagen). After washing with column buffer containing 60 mM imidazole the ERK2 protein was eluted with column buffer containing 1 M imidazole. ERK2 25 containing fractions were identified by SDS-PAGE and dialyzed into Mono Q A-buffer (25 mM Tris HCL, pH 7.5 25 mM NaCl, 1 mM EDTA). The dialysate was loaded onto a HR5/5 Mono Q FPLC column (Pharmacia) and eluted with a 30 ml gradient from Mono Q A-buffer to the same buffer containing 250 mM NaCl (Mono Q B-buffer) at 1 ml/min collecting 30 fractions. Fractions #19-20 and #27-28 typically contained the peak amounts of two ERK2 conformers, as 30 identified by western blotting. Only the first fraction was applied to HR 5/5 Phenylsuperose FPLC (Pharmacia) and eluted with a 15 ml gradient from 25 mM Tris, pH 7.5, 150 mM NaCl, 1

mM EDTA, 1 mM DTT to the same buffer containing 25 mM NaCl and 60% ethylene glycol with a flow rate from 0.5 ml/min decreasing to 0.1 ml/min at the end of the gradient. Homogeneous ERK2 typically eluted after 13-14 ml.

For activation of ERK2 to the active PK40 form about 1 mg of purified histidine tagged ERK2 was mixed with 25 ml of CM-Sepharose eluate fraction prepared from bovine brain extracts according to Roder H.M. et al., J. Neurochem. 64, 2203-2212 (1995), adjusted to 2 mM Mg^{2+} /0.5 mM ATP and incubated for 2 hrs at 37°C. The mixture was dialyzed twice into 1 l each of Ni^{2+} column binding buffer (20 mM Tris, pH 2.9, 500 mM NaCl, 5 mM imidazole) to remove traces of DTT and loaded onto 0.3 mL Ni^{2+} charged resin (Novagen) at 25 mL/hr. After washing with 10 mL column buffer followed by 4 mL column buffer containing 40 mM imidazole homogeneous activated PK40^{erk2} was eluted with 4 mL column buffer containing 1 M imidazole. The product was dialyzed extensively into 10 mM HEPES, pH 7.0, 1 mM EDTA to remove imidazole and traces of Ni^{2+} , and finally into 10 mM HEPES, pH 7.0, 1 mM EDTA, 1 mM DTT.

Assays for Kinase Activity:

PK40^{erk2} was assayed in 50 μ l 25 mM HEPES, pH 7.0, 1 mM $MgCl_2$, 1 mM DTT, 0.25 mM ATP, 1 mg/mL BSA using 15-30 ng of PK40^{erk2} and 0.1 mg/mL myelin basic protein (Sigma) as a substrate.

PKC was assayed in 50 μ l 25 mM HEPES, pH 7.0, 10 mM $MgCl_2$, 2 mM $CaCl_2$, 1 mM EDTA, 1 mM DTT, 0.25 mM ATP, 0.2 mg/mL phosphatidylserine, using 20 ng PKC and 0.08 mg/mL histone III-S as a substrate.

The catalytic subunit of PKA was assayed in 50 μ l 25 mM HEPES, pH 7.0, 10 mM $MgCl_2$, 1 mM EDTA, 1 mM DTT, using 70 ng PKA and 0.1 mg/mL human recombinant tau protein as a substrate.

cdc2 kinase was assayed in 50 μ l 25 mM HEPES, pH 7.0, 1 mM Mg^{2+} , 0.25 mM ATP (150-300 cpm/pmole), 1 mM DTT, using 0.5 ng cdc2 kinase, 5 μ g human recombinant tau as substrate, and 0.1 mg/mL BSA as a carrier.

Determination of Potency of Kinase Inhibitors

Enzyme, substrate and inhibitor were preincubated for 5-10 min at 4°C in assay buffers

containing a final concentration of 2% DMSO before initiating the reaction with 0.25 mM $\gamma^{32}\text{P}$ -ATP. Samples were incubated for 30 min at 37°C and reactions were terminated with 10% trichloroacetic acid/2% sodium pyrophosphate (TCA/PPA), followed by filtration over a glass fiber filtermat (type A) with a cell harvester (Tomtec). The filtermats were washed twice for several hours with TCA/PPA until all background radioactivity was removed. Precipitable counts were quantitated directly on the filtermat with a microbeta scintillation counter system (Wallac-Pharmacia). Inhibitor data were subjected to curve fitting and IC_{50} values were calculated from these curves using the GraphIt program.

10 **Example 6: Determination of Potency of Inhibitors to Prevent AD-like Tau Hyperphosphorylation in SY5Y Cell Model**

In vitro, and presumably also in vivo, tau is a substrate for multiple kinases. The main problem to evaluate inhibitors specifically interfering with the AD-like hyperphosphorylation of tau is to distinguish clearly between normal and abnormal phosphorylation of tau in model systems. In the cell line SY5Y comparisons can be made with tau associated with tangles from human AD brain, because of its human origin. As in fetal brains, SY5Y cells express only one of the 6 splice isoforms of tau, simplifying the survey of tau phosphorylation states.

15 **Methods**

SKNSH-SY 5Y cells were plated on fibronectin-coated 6 well (30 mm²) culture dishes (Biocoat®, Collaborative Biomedical Products, Inc.) and grown to confluence in 5 mL of 50% D-MEM/ 50% F-12 Nutrient Mixture (Ham) supplemented with 15% heat-inactivated bovine serum (JRH Bioscience), 0.1 mM non-essential amino acids solution, 2 mM glutamine and —pen/strep/fungizone (GibcoBRL Life Technologies, Inc.). Cell culture medium was changed every 48 hours.

25 For drug testing, cells were routinely pretreated with inhibitors in 1 mL (30 mm²) for 60 min at concentrations of 30 nM, 100 nM, 300 nM, 1 mM, 3 mM and 10 mM. Compound stocks were all at 10 mM in DMSO and dilutions were made in DMSO. Cells were then treated with 1 μM okadaic acid (ammonium salt; LC Laboratories, dissolved at 1 mM in DMSO) for 90 min. All experiments, including controls, contained a final concentration of between 0.5 and 1% DMSO.

30 Cells were detached from 30 mm² plates and suspended into 1 mL of ice-cold PBS by gentle trituration, transferred into microcentrifuge tubes and sedimented for 12 seconds at 14,000

x g. The supernatant was removed and cells were lysed in 250 µl cold homogenization buffer (50 mM MES, pH 5.8, 5 mM sodium pyrophosphate, 50 mM p-nitrophenylphosphate, 1 µM okadaic acid, 2 mM Na-orthovanadate, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 10% glycerol, 10 µM leupeptin, 1 µM pepstatin, 1 mg/mL aprotinin, 10 µM chymostatin, 1 mM PMSF, and 1% TRITON® x100) and vortexed briefly to aid in lysis. Cell debris was removed by centrifugation at 14,000 x g for 5 minutes at 4°C and cell supernatants were analyzed by anti-ERK2 and anti-tau Western-blotting as described below.

25 mL of total cell lysate was run on a 10% tris-glycine polyacrylamide gels (Novex, 1.5 mm x 10 well) at 100 volts for 2.5 hours and Western-blotted on nitrocellulose (Novex) overnight at 23 volts or 1.5 hrs at 100V in transfer buffer [Towbin et al. Proc. Natl. Acad. Sci. USA 76, 4350-4354 (1979)] at 4°C. Blots were analyzed for ERK2 and phosphotyrosine immunoreactivity with anti-ERK1+2 (Z033; Zymed Laboratories, Inc.; 1:5,000) and anti-phosphotyrosine (4G10; Upstate Biotechnology Inc.; 1:1,000) mAbs. Blots were also analyzed for phosphorylation-sensitive Tau immuno-reactivity with mAb Tau-1 (Boehringer Mannheim; 1:5,000) and phosphorylation dependent mAb AT8 against FHF-tau (Biosource International; 1:200). Total Tau populations were detected by Tau-1 immunoblotting after treating blots for 16 hrs at 37°C with 100 units/mL alkaline phosphatase (Gibco BRL) in 5 mL of 50 mM Tris-HCl (pH 8.5), 0.1 mM EDTA. All blots were developed using ECL (enhanced chemiluminescence) Western blotting protocol (Amersham Life Science) with horseradish peroxidase-linked sheep anti-mouse secondary antibody and analyzed on Kodak X-OMAT AR scientific imaging film. Films were scanned into Adobe Photoshop and imported into NIH Image 1.44, where densitometric analysis was performed. Changes in tau phosphorylation were assessed by normalizing densitometrically determined mAb Tau-1 immunoreactivities in cell extracts to Tau-1 reaction after dephosphorylation on the blot. Ratios of Tau-1 reactivity prior to and after dephosphorylation were expressed in % relative to the ratio obtained from control cells not treated with okadaic acid (100%). Proteins isolated from neonatal rat brain were used for comparison in some experiments.

Results

The potency of the compounds of the invention tested, including CII and CIII, in the *in vitro* kinase assay was well correlated with their inhibitory activity of tau hyperphosphorylation in the cell. Moreover, each of the compounds demonstrated a correlation between inhibition of

ERK2 and tau hyperphosphorylation.

Correlation of potencies of inhibition of PK40 activity in vitro, and of OA-induced ERK2 and tau phosphorylation in SY5Y cells. ERK2 phosphorylation was quantified as the ratio of low mobility/total ERK2, densitometrically determined from ERK2 Western-blots (e.g. of Fig. 1). Tau hyperphosphorylation was expressed as densitometrically measured Tau-1 immunoreactivity normalized to total Tau-1 reactivity after unmasking of the epitope by phosphatase treatment of the blots.

In Fig. 2, tau from untreated SY5Y cells is compared to the completely hyper/dephosphorylated state (accomplished by treatment in vitro with PK40(ERK2) and phosphatase 2B, respectively), and to PHF-tau from AD brains with regard to Tau-1 immunoreactivity and electrophoretic mobility. Tau proteins were analyzed as isolated from tissue in comparison to tau exhaustively dephosphorylated with PP2B calcineurin), or hyperphosphorylated in vitro with PK40. Western-blots were stained with mAb Tau-1 (Fig. 2A, B, upper panels) or AT8 (Fig. 2C, lanes 4-6). Relative gel mobilities and loading were visualized by Tau-1 after complete unmasking of the epitope by phosphatase treatment on the blot (Fig. 2A, B, lower panels; Fig. 2C, lanes 1-3). The phosphorylation of fetal tau appears to be similar to SY5Y tau. In either case hyperphosphorylation by PK40 completely abolishes residual Tau-1 reactivity and induces a small additional mobility shift. By these criteria SY5Y tau hyperphosphorylated in vitro by PK40 is indistinguishable from tau hyperphosphorylated in situ after okadaic acid induction, and from PHF-tau. Soluble fractions of PHF-tau were extracted from purified PHF by water or SDS.

Figure 2 shows that in SY5Y cells most of the potential Tau-1 reactivity is already masked by phosphorylation, and the electrophoretic mobility of tau is close to maximally retarded. By the criteria of Fig. 2, the phosphorylation state of tau in SY5Y cells does not appear to be substantially different from tau in neonatal rat brains (Fig. 2C). This probably applies to tau from adult brains as well, as newer data avoiding post-mortem artifacts in isolating tau argue against the previously held notion that the fetal phosphorylation state is higher than in the adult state.

Hyperphosphorylation with PK40(ERK2) in vitro does induce a small but detectable change in tau properties as isolated from SY5Y cells. Only in this state the electrophoretic mobility of tau matches exactly the gel mobility of the corresponding

pathologically phosphorylated splice isoform extracted from tangles (Fig. 2C). In cells, the same abnormal phosphorylation state can be induced by inhibition of protein phosphatase 2A with okadaic acid.

Example 7:

Methods

Neonatal rat tau hyperphosphorylated *in vitro* by PK40 with or without prior dephosphorylation by PP2B. Equal amounts of purified 32P-hyperphosphorylated tau samples were digested with trypsin, and peptides were analyzed by 2D electrophoresis. The results are shown in Figure 3. Labeling of peptides was quantified by counting (cpm displayed for each spot). Comparison of total cpm showed that dephosphorylation liberated only about 1/5th of the available ERK2 sites.

Results

In order to demonstrate that the small changes in immunochemical and gel mobility properties observed in the data presented herein is useful and a relevant model for assessing the large AD-like hyperphosphorylation effects which occur the degree of dephosphorylation/hyperphosphorylation of tau in neonatal rat cells was observed. The small change of tau associated with abnormal AD-like phosphorylation *in vitro* and in cells does not necessarily reflect a small change in the phosphorylation state. As shown in Figure 3 the degree of hyperphosphorylation of tau from fetal/neonatal rat brains by PK40(ERK2) which were not pre-dephosphorylated is only about 20% lower than the degree of dephosphorylation observed when tau is dephosphorylated completely prior to hyperphosphorylation. In addition, the two-dimensional phosphopeptide maps of tau in this comparative study are qualitatively indistinguishable (Fig. 3).

Example 8: Inhibitors of PK40 Prevent Abnormal AD-like Hyperphosphorylation.

Methods

Compound CIII prevents ERK2 phosphorylation and tau hyperphosphorylation in a correlated fashion (Fig. 4). Compared to control cells (lane C) 1 μ M okadaic acid induced ERK2 phosphorylation/activation, as shown by a small gel mobility shift of ERK2 (lane OA) and

induction of reactivity with a mAb sensitive to the double phosphorylation of the regulatory Thr-Glu-Tyr motif of ERK2 (anti-active ERK2). Both effects were prevented by $\geq 1 \mu\text{M}$ compound CIII (IC₅₀ at about $1 \mu\text{M}$, complete at $10 \mu\text{M}$). Highly correlated with the effect on ERK2 was the

5 prevention of OA induced tau hyperphosphorylation, as tracked by elimination of Tau-1 reactivity and prevention of a small gel mobility shift typical of AD-like tau. Note that at $10 \mu\text{M}$, with ERK2 activation completely arrested, the tau phosphorylation state (including the phosphoisoform pattern) remains unaltered compared to normal phosphorylation in control cells.

10 Prevention of tau hyperphosphorylation by the preferred compound CIII (Fig. 1). Okadaic acid at $1 \mu\text{M}$ induced the complete elimination of the Tau-1 epitope (upper panel) as in PHF-tau of AD. The shift in electrophoretic mobility corresponding to human PHF-tau was visualized by phosphatase treatment of duplicate Western-blot (lower panel) to recover the masked Tau-1 epitope. The compound CIII prevents the tau hyperphosphorylation in a dose
15 dependent manner. At fully effective doses ($>1 \mu\text{M}$) tau remained in a phosphorylation state similar to the normal state in control cells (lane C). Tau in normal cells not treated by okadaic acid is phosphorylated to a substantial degree; this normal phosphorylation was apparently not affected by CIII. The ratio of densitometrically measured Tau-1 signal over the Tau-1 signal after dephosphorylation, a normalizing measure of the total tau population, formed the basis for
20 quantitative analysis to determine IC₅₀ values.

Results

— Inhibitors of PK40(ERK2), exemplified by CIII, indeed prove capable of preventing abnormal AD-like hyperphosphorylation in a SY5Y cell model system. Fig. 1 shows that
25 increasing concentrations of CIII prevent the okadaic acid provoked hyperphosphorylation of tau. This protective effect is highly correlated with the prevention of the activating phosphorylation of ERK2 in the same cells. By binding to ERK2, CIII is able to both inhibit the activity of ERK2 as well as its activation (either via autophosphorylation or via another kinase), with both effects essentially eliminating cellular tau hyperphosphorylating activity. Moreover, the normal cellular
30 phosphorylation state of tau is not affected by CIII in the same concentration range, demonstrating a case of cellular selectivity (not shown).

Example 9: Determination of Potency of Inhibitors to Prevent AD-like Tau Hyperphosphorylation in Rat Hippocampal Brain Slices

5 *Methods*

Adult male Long-Evans rats were subjected to CO₂ anesthesia and sacrificed by decapitation. Brains were rapidly removed (<2 min) and whole hippocampus was dissected using a blunt spatula. Hippocampi were cut into 450 mM slices using a McIlwain tissue chopper and placed into ice cold low Ca²⁺ Krebs-Bicarbonate buffer (pH 7.) of the following composition
10 in mM: NaCl, 124; KCL, 3.33; CaCl₂, 0.01; KH₂PO₄, 1.25; MgSO₄ 1.33; nAhco₃, 25.7; D-glucose, 10; HEPES, 20. The slices were separated and placed, 5-8 per tube, into 5 mL of low Ca²⁺ buffer and incubated for at least 30 min at 33 - 34°C with water saturated oxygenation (95% O₂, 5% CO₂). After 30 min the solution was replaced with buffer containing a physiological level of Ca²⁺ (1.3 mM) and incubated for an additional 30 min.

15 After a total equilibration period of at least 1 hr, the slices were pretreated with vehicle or inhibitor at concentrations ranging from 30 nM to 10 µM for 1 hr, and then exposed to either vehicle or okadaic acid for 90 min. After treatment, the buffer was removed and the slices were sonicated for 10 - 20 sec in 500 µl of homogenization buffer (100 mM KH₂PO₄, pH 6.5, 2 mM EGTA, 2 mM EDTA, 1 µM okadaic acid and the following protease inhibitors : aprotinin
20 (10µg/ml); leupeptin (10 µM); chymostatin (40 µM); PMSF (100 µM) and pepstatin (6 µg/ml).

Following sonication, the samples were centrifuged 16,000 x g for 30 min and the supernatants were removed. After boiling of the supernatants for 5 mn at 100°C the concentration of protein was determined by the BCA assay (Pierce) using BSA as standard and samples were normalized to equal protein concentration.

25 Aliquots of the heat stable supernatants were separated on 10% SDS-PAGE and Western-blotted with phosphorylation-sensitive tau mAb Tau-1 and PHF-tau mAb AT8 as described for SY5Y studies. Blots were developed by an ECL kit (Amersham Life Science). AT8 immunoreactivity was quantitated on Kodak XOOMAT AR film using a Biorad imaging densitometer GS 670, the strongest signals not exceeding an O.D. of 12.

30 *Results*

Freshly isolated hippocampal brain slices from adult rats were used for similar experiments under conditions more relevant to the brain (Fig.5). Again, okadaic acid induced

AD-like tau hyperphosphorylation, while CII prevented it with the same IC50 as in SY5Y cells (0.1 μ M).

Okadaic acid induced reactivity with the novel phosphorylation dependent mAb AP422. This response was inhibited at the same dose as the response with the more conventional mAb AT8 (Fig.5), indicating a single tau hyperphosphorylating activity. In vitro reactivity of tau with this mAb can only be induced by ERK2, but not other candidate tau kinases (e.g. cdk, GSK3), providing an independent criterion that ERK2 is the relevant drug target.

The intensity of AP422 reactivity induced by PK40(ERK2) in vitro matches that of isolated PHF-tau from AD-brain (not shown). In contrast, even with the most conservative precautions to avoid post-mortem dephosphorylation in rat brains, AP422 reactivity is completely absent in normal adult tau. This suggests that tau hyperphosphorylation in AD is qualitatively abnormal, and does not involve enhanced activity of normal kinases, but rather the pathological activation of ERK2 as an abnormal tau kinase.

Prevention of AD-like tau hyperphosphorylation in adult rat hippocampal brain slices. In an experimental paradigm similar to SY5Y cells tau hyperphosphorylation is prevented by derivative CII at similar doses as in SY5Y cells.

Note that the results with AP422, currently the most specific criterion for AD-like tau hyperphosphorylation, are identical to those with the commonly used mAb AT8, indicating that ERK2 alone is responsible for all okadaic acid induced changes in tau phosphorylation.

Table 1: Properties of Preferred Compounds as Inhibitors of ERK2 (PK40), Activation of ERK2, cdc2, and Tau Hyperphosphorylation in Biological Models of PHF-tau formation (IC₅₀ values in μ M)

	CII	CIII
5		
PK40 (ERK2)	0.044	>>30
cdc2	0.044	3.8
PKA	0.65 ^{a)}	>100
PKC	0.65 ^{a)}	>100
Inhibition in SY5Y	0.57	5.7
10 cells ^{b)} of ERK2 activation		
tau hyperphos.	0.58	3.6
Inhibition of tau	0.18	0.9
15 hyperphos. in brain slices ^{b)}		

^{a)} = partial inhibition only


^{b)} = means of triplicate determinations

^{c)} = concomitant inhibition of normal tau phosphorylation

20

We claim:

1. A composition of matter comprising: (Formula I)



wherein Z is O or 2H,

R1 is H, OH, CO₂R₉, CONHR₉, CH₂OR₉, or CONR₉, R₁₀;

R2 is H or OH; R3 is H or OH; R4 is H or OH;

R5 is H, OH, NR₉R₁₀, NHCOR₉, OCOR₉, OCR₉, halide, COOR₉, or CONR₉R₁₀;

R6 is H, OH, NR₉R₁₀, NHCOR₉, OCOR₉, OCR₉, halide, COOR₉, or CONR₉R₁₀;

R7 is H, OH, O or halide;

R8 is H, OH, halide or nothing (when R7 is O);


R9 is an alkyl of 1-6 carbons, a cycloalkyl of 3-6 carbons or H;

R10 is an alkyl of 1-6 carbons, a cycloalkyl of 3-6 carbons or H.

2. The composition of matter of claim 1, wherein Z is O; R1 is OH, CO₂R₉, CONHR₉ or CH₂OR₉; R4 is H; R5 is H; R6 is H; and R8 is H.


3. The composition of matter of claim 1, wherein Z is O; R1 is CO₂CH₃ or CONHCH₃; R2 is H; R3 is OH; R4 is H; R5 is H; and R6 is H.

4. The composition of matter of claim 1, wherein the composition of matter is selected from the group consisting of:



SUBSTITUTE SHEET (RULE 26)

5. A pharmaceutical composition comprising:
the composition of matter of claim 1, and
the pharmaceutically-acceptable carrier.
- 5 6. A pharmaceutical composition comprising:
the composition of matter of claim 2, and
a pharmaceutically-acceptable carrier.
7. A pharmaceutical composition comprising:
10 the composition of matter of claim 3, and
a pharmaceutically-acceptable carrier.
8. A pharmaceutical composition comprising:
the composition of matter of claim 4, and
15 a pharmaceutically-acceptable carrier.
9. The pharmaceutical composition of claim 5 in an oral dosage form.
10. The pharmaceutical composition of claim 6 in an oral dosage form.
- 20 11. The pharmaceutical composition of claim 7 in an oral dosage form.
12. The pharmaceutical composition of claim 8 in an oral dosage form.
- 25 13. A method for inhibiting in a subject a kinase which binds a compound of Formula I
comprising:
administering to a subject in need of such treatment the compound of Formula I as
follows:



wherein Z is O or 2H,

R₁ is H, OH, CO₂R₉, CONHR₉, CH₂OR₉, or CONR₉, R₁₀;

R₂ is H or OH; R₃ is H or OH; R₄ is H or OH;

R⁵ is H, OH, NR⁹R₁₀, NHCOR⁹, OCOR⁹, OCR⁹, halide, COOR⁹, or CONR⁹R₁₀;

R6 is H, OH, NR₉R₁₀, NHCOR₉, OCOR₉, OCR₉, halide, COOR₉, or CONR₉R₁₀:

R7 is H, OH, O or halide;

R8 is H, OH, halide or nothing (when R7 is O);


R⁹ is an alkyl of 1-6 carbons, a cycloalkyl of 3-6 carbons or H;

R10 is an alkyl of 1-6 carbons, a cycloalkyl of 3-6 carbons or H.

14. The method of claim 13, wherein Z is O; R1 is OH, CO₂R9, CONHR9 or CH₂OR9; R4 is H; R5 is H; R6 is H; and R8 is H.

15. The method of claim 13, wherein Z is O; R1 is CO₂CH₃ or CONHCH₃; R2 is H; R3 is OH; R4 is H; R5 is H; and R6 is H.

16. The method of claim 10, wherein the compound is selected from the group consisting of:




17. The method of any one of claims 13-16, wherein the subject has a dementia characterized by tau hyperphosphorylation and wherein said compound is administered in an amount effective to inhibit said hyperphosphorylation.

18. The method of claim 17, wherein the hyperphosphorylation is characteristic of Alzheimer's disease and wherein the compound is administered in an amount sufficient to inhibit phosphorylation activity of ERK2 which is characteristic of abnormal tau hyperphosphorylation

in Alzheimer's disease.

19. A method for inhibiting in a subject abnormal cell proliferation comprising:
administering to a subject in need of such treatment a compound of Formula I as follows:



wherein Z is O or 2H,

R1 is H, OH, CO₂R₉, CONHR₉, CH₂OR₉, or CONR₉, R₁₀;

R2 is H or OH; R3 is H or OH; R4 is H or OH;

R5 is H, OH, NR₉R₁₀, NHCOR₉, OCOR₉, OCR₉, halide, COOR₉, or CONR₉, R₁₀;

R6 is H, OH, NR₉R₁₀, NHCOR₉, OCOR₉, OCR₉, halide, COOR₉, or CONR₉, R₁₀;

R7 is H, OH, O or halide;

R8 is H, OH, halide or nothing (when R7 is O);

R9 is an alkyl of 1-6 carbons, a cycloalkyl of 3-6 carbons or H;

R10 is an alkyl of 1-6 carbons, a cycloalkyl of 3-6 carbons or H,

in an amount effective to inhibit in the subject said kinase activity, in an amount effective to inhibit in the subject said unwanted proliferation.


20. The method of claim 19, wherein:

Z is O; R1 is OH, CO₂R₉, CONHR₉ or CH₂OR₉; R4 is H; R5 is H; R6 is H; and R8 is H.

21. The method of claim 19, wherein: Z is O; R1 is CO₂CH₃ or CONHCH₃; R2 is H; R3 is OH; R4 is H; R5 is H; and R6 is H.


22. The method of claim 19, wherein:

the composition of matter is selected from the group consisting of:



23. The method of any one of claims 19-22, wherein the abnormal cell proliferation results from a cancer expressing an abnormal level of a cdc2 kinase.


24. A composition of matter comprising:



wherein, $Z=O$ or $2H$ (in which case the double bond is two single bonds).


25. The composition of claim 24 wherein Z is O , $R_{13} = H$ and $R_{13}' = H$.

26. The composition of claim 24 selected from the group consisting of



SUBSTITUTE SHEET (RULE 26)

27. A composition of matter comprising



5 wherein, $Z=O$ or $2H$; R_{13} , $R_{13}' = H$ or OP ; and $R_{14} = O$, H , OH or OP . Preferably, Z is O and R_{13} and R_{13}' are H .

28. The composition of claim 27 wherein $Z=O$ and R_{13} and $R_{13}' = H$.




Fig. 1

SY 5Y cell

Neonatal Rat





Fig. 2A

Fig. 2B




Fig. 2C

SUBSTITUTE SHEET (RULE 26)

PP2B / PK40

PK40




Fig. 3






Fig. 4




Fig. 5

INTERNATIONAL SEARCH REPORT

International Application No

PCT/99/04369

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/22 A61K31/55 //(C07D487/22,243:00,209:00,209:00,209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 02488 A (CEPHALON, INC.) 3 February 1994 (1994-02-03) cited in the application claims 1,18,30-36 ---	1,5,24, 27
A	WO 95 07911 A (CEPHALON, INC.) 23 March 1995 (1995-03-23) cited in the application claims 1-3,10-12 ---	1,5,24, 27
A	WO 94 27982 A (CEPHALON, INC.) 8 December 1994 (1994-12-08) cited in the application abstract; claims 1,15-17,27 ---	1,5,24, 27
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 October 1999

Date of mailing of the international search report

27/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT 99/04369

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 643 966 A (KYOWA HAKKO KOGYO K. K.) 22 March 1995 (1995-03-22) cited in the application claims 1,3,4; tables 1,2 ---	1,5,27
A	WO 94 04541 A (THE UPJOHN CO.) 3 March 1994 (1994-03-03) cited in the application claims 1,24 ---	1,5,27
A	US 4 923 986 A (C. MURAKATA ET AL.) 8 May 1990 (1990-05-08) cited in the application abstract; claims ---	1,5,27
A	EP 0 323 171 A (KYOWA HAKKO KOGYO CO., LTD.) 5 July 1989 (1989-07-05) cited in the application claims & US 4 877 776 A cited in the application ---	1,5,27
A	EP 0 545 195 A (BANYU PHARMACEUTICAL CO., LTD.) 9 June 1993 (1993-06-09) claims 1-3; examples ---	24
P,X	D. A. RILEY ET AL.: TETRAHEDRON LETTERS, vol. 40, no. 20, 14 May 1999 (1999-05-14), pages 3929-32, XP004163783 page 3929, abstract; schemes 1 and 2 -----	1,4,24, 27

INTERNATIONAL SEARCH REPORT

International application No.
PCT/99/04369

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13-23
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 24-27
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 13-23 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 13-23

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Claims Nos.: 24-27

In claim 24, the substituents R11, R12, R13, R13' and P are not defined.
 In claim 25, the substituents R11, R12 and P are not defined.
 In claim 26, the substituents R13, R13' and P are not defined.
 In claim 27, the substituent P is not defined.
 It appears that the definitions given on page 6, line 15 to page 7, line 3 should apply. Therefore the search of claims 24 to 27 was carried out in the light of said definitions given in the description.

INTERNATIONAL SEARCH REPORT

International Application No

Information on patent family members

PCT 99/04369

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9402488	A	03-02-1994	AT 152111 T	15-05-1997
			AU 675236 B	30-01-1997
			AU 4688193 A	14-02-1994
			BR 9306789 A	08-12-1998
			CA 2140924 A	25-01-1994
			DE 69310178 D	28-05-1997
			DE 69310178 T	25-09-1997
			DK 651754 T	27-10-1997
			EP 0651754 A	10-05-1995
			EP 0768312 A	16-04-1997
			ES 2101331 T	01-07-1997
			GR 3023817 T	30-09-1997
			HU 71239 A	28-11-1995
			JP 8501080 T	06-02-1996
			NO 950242 A	07-03-1995
			NO 990542 A	05-02-1999
			NZ 254662 A	26-11-1996
			US 5461146 A	24-10-1995
			US 5621100 A	15-04-1997
			US 5756494 A	26-05-1998
			US 5621101 A	15-04-1997
			US 5741808 A	21-04-1998
WO 9507911	A	23-03-1995	US 5468872 A	21-11-1995
			AU 693480 B	02-07-1998
			AU 7836394 A	03-04-1995
			CA 2171561 A	23-03-1995
			EP 0719268 A	03-07-1996
			FI 961236 A	15-03-1996
			HU 74679 A	28-01-1997
			JP 9502730 T	18-03-1997
			NO 961087 A	13-05-1996
			NZ 274355 A	24-03-1997
			US 5516772 A	14-05-1996
WO 9427982	A	08-12-1994	AT 165097 T	15-05-1998
			AU 679752 B	10-07-1997
			AU 6960794 A	20-12-1994
			CA 2163904 A	08-12-1994
			DE 69409641 D	20-05-1998
			DE 69409641 T	26-11-1998
			EP 0699204 A	06-03-1996
			EP 0839814 A	06-05-1998
			ES 2118414 T	16-09-1998
			FI 955709 A	03-01-1996
			NO 954816 A	26-01-1996
			US 5516771 A	14-05-1996
			US 5654427 A	05-08-1997
EP 643966	A	22-03-1995	WO 9420106 A	15-09-1994
WO 9404541	A	03-03-1994	AU 4787693 A	15-03-1994
			CA 2140653 A	03-03-1994
			EP 0655066 A	31-05-1995
			JP 8500112 T	09-01-1996
US 4923986	A	08-05-1990	WO 8807045 A	22-09-1988
			DE 3752123 D	06-11-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT 99/04369

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4923986 A		DE 3752123 T	14-05-1998
		EP 0303697 A	22-02-1989
EP 323171 A	05-07-1989	JP 1168689 A	04-07-1989
		JP 2075288 C	25-07-1996
		JP 7113027 B	06-12-1995
		DE 3852288 D	12-01-1995
		DE 3852288 T	13-04-1995
		US 4877776 A	31-10-1989
EP 545195 A	09-06-1993	AT 130617 T	15-12-1995
		AU 650376 B	16-06-1994
		AU 2963792 A	03-06-1993
		BG 61036 B	30-09-1996
		BG 97970 A	25-04-1994
		CA 2083534 A	30-05-1993
		CN 1075482 A,B	25-08-1993
		DE 69206242 D	04-01-1996
		DE 69206242 T	28-03-1996
		DK 545195 T	18-12-1995
		ES 2079774 T	16-01-1996
		FI 925422 A	30-05-1993
		GR 3018527 T	31-03-1996
		HU 65699 A	28-07-1994
		HU 9500172 A	28-07-1995
		IL 103844 A	30-09-1997
		WO 9311145 A	10-06-1993
		JP 2629542 B	09-07-1997
		JP 6128283 A	10-05-1994
		MX 9206847 A	30-06-1993
		NO 178929 B	25-03-1996
		NZ 245203 A	27-07-1997
		PL 304729 A	09-01-1995
		US 5591842 A	07-01-1997
		US 5589365 A	31-12-1996
		US 5668271 A	16-09-1997
		US 5643760 A	01-07-1997
		CN 1073948 A,B	07-07-1993
		PL 172316 B	30-09-1997
		ZA 9209263 A	25-05-1993